Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
Popular Articles
Cellulite Cream

Another Mystery In B Lymphocyte Development Solved By NYU School Of Medicine Pathology Researchers
A new study published online in Nature Immunology ahead of the June 2009 print issue has found that homologous immunoglobulin (lg) alleles pair up in the nucleus at stages that coincide with V(D)J recombination of the heavy and light chain (Igh and Igk) loci. Researchers led by Jane A. Skok Ph.D., assistant professor in the Department of Pathology at NYU School of Medicine and a member of the NYU Cancer Institute, showed that the V(D)J recombinase, which consists of the RAG1 and RAG2 proteins, mediates this pairing and helps ensure that only one allele undergoes recombination at a time (a process known as allelic exclusion).
generic viagra online
Drive For Good Quality Medicines, Foods Reinforced By USP Agreements With Chinese Drug Authorities
As part of its efforts to improve the quality of medicines and food ingredients worldwide, the U.S. Pharmacopeial (USP) Convention this week reached three new cooperative agreements with Chinese drug control authorities. Because Chinese manufacturers supply so much of the world"s drug and food ingredients, these agreements-coupled with three previous agreements between USP and other government organizations in China-mark a significant commitment to ensure that concerns about quality are addressed. USP is a scientific, nonprofit organization that sets standards for the quality of prescription and over-the-counter drugs that are enforced by the U.S. Food and Drug Administration (FDA) in the United States. USP also sets standards for the quality of food ingredients and dietary supplements; these and USP"s drug standards are used in more than 130 countries.
News of the day
Symposium On Synthetic Biology, July 9 -10, 2009
The emerging field of synthetic biology uses engineering techniques to manipulate biological materials, enabling scientists to create new biological systems or even engineer new life forms. Though these technologies could lead to the creation of beneficial materials and applications for human health, they also raise a host of public policy, legal, and ethical questions.
Health Insurance

Weakening IP Would Threaten R&D Investment

A proposal to dramatically weaken intellectual property legislation could lead to the loss of thousands of high-skill jobs and millions of dollars of global investment in Australian R&D, Medicines Australia chief executive Ian Chalmers said today. "Weakening Australia"s IP regime would have a negative impact on Australian R&D and is fundamentally at odds with the Prime Minister"s own commitment to make innovation a way of life in Australia," Mr Chalmers said. Generic medicines manufacturer Hospira is seeking changes in the IP laws to allow generic copies of innovative medicines to be manufactured for export while those medicines are still patent-protected, effectively cutting short patent life. "The idea has no merit beyond the commercial agenda of a single pharmaceutical company and could spell disaster for medical innovation," Mr Chalmers said. "We are a country that boasts a sustainable competitive advantage in attracting and conducting high-quality, outcomes-oriented R&D. Australia"s pharmaceutical industry alone attracts more than $1 billion a year in global R&D investment. "That investment generates smart jobs, provides highly skilled work for scientists and supports Australia"s aspiration to become a global leader in medical innovation. "Such investment depends heavily on a consistent and predictable business environment with strong protection of IP rights. If predictability is undermined and IP legislation weakened, global companies will seek other investment destinations. "Apart from the potentially disastrous economic ramifications, there are other reasons why weakening Australia"s IP laws would be counterproductive. "It would contravene Australia"s obligations under the World Trade Organisation"s intellectual property laws. It would also likely provoke retaliatory measures by our key trading partners, with possible market access implications for our $4 billion in pharmaceutical exports. "It would damage multi-lateral efforts to implement globally harmonised standards of IP protection. It would also undermine the rights of patent holders in Australia. "From trade, innovation and economic perspectives, a move to effectively shorten patents in Australia would have dramatic consequences. It just doesn"t stack up." Medicines Australia


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009